GSK Institute for Infectious Diseases and Public Health to partner with Tsinghua University to tackle global public health challenges

GSK today announced a Memorandum of Understanding Agreement between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University School of Medicine (Tsinghua). This 5 year public-private partnership will take on public health challenges in China and globally through scientific and talent exchange as well as joint research programs.

The new GSK Institute for Infectious Diseases and Public Health, announced in March, is an expansion of the GSK R&D China hub that was first established in 2007. The new Institute aims to create sustainable, affordable treatment options for patients in China by aligning GSK’s R&D capabilities in infectious diseases with the country’s public health interests, and will act as a focal point for academics, government, healthcare providers and regulators. Focusing initially on treatments for infectious diseases, the Institute will bring a multi-year investment of over RMB 200 million, and more than 20 dedicated experts in medicine discovery, development and epidemiology. Research to support the development in China of key assets from GSK’s innovative infectious diseases pipeline will be led by the Institute, including clinical assets for HIV and multi-drug resistant bacterial infections.

Tsinghua is a leading public university with a longstanding commitment to academic excellence and public service, and looking forward the field of medical science will be a strategic focus. To develop a strong healthcare talent base, Tsinghua plans to build integrated training capabilities in drug discovery, translational research, product development, regulatory science, public health advocacy and policy. This partnership will bring GSK’s extensive expertise in each of these areas to the University. The collaboration will also support Tsinghua’s annual public health forums to bring together experts from across disciplines to discuss and address specific global and China healthcare issues.

Professor Yong QIU, President of Tsinghua University commented, “Tsinghua has a longstanding commitment to serve the greater good of the society. Partnering with a leading pharmaceutical company like GSK will allow us to leverage its expertise in drug discovery and development to address infectious disease healthcare challenges. It is also an excellent opportunity for the School of Medicine to provide students with real world knowledge from the industry’s perspective, and better prepare them to be the health care leaders of tomorrow.”

Sir Andrew Witty, CEO, GSK commented, “The global challenges posed by infectious diseases require innovation and partnership approaches between institutions, industry and government. We are honored to enter into this partnership with Tsinghua University which underlines the importance that GSK places on working with Chinese experts to collaborate and develop solutions that address specific public health challenges in China.”

Professor Chen DONG, Executive Dean, TUSOM, said, “In the past 15 years, the Tsinghua University School of Medicine has been devoted to building world-class research capabilities and training global talents. We are very pleased to partner with GSK to tackle global health—an area where we see the future expansion for our school.”

Leading the GSK Institute, Zhi HONG, Senior Vice President and head of GSK’s Infectious Diseases R&D unit said, “We are committed to creating a learning platform at Tsinghua to develop talent and capability. Working side by side with Tsinghua scientists, we want to build a new form of public-private partnership and deepen trust with partners who share our value and commitment to global public health.”

The partnership with Tsinghua is the latest example of GSK delivering on its publically stated commitment to be “in China, with China, for China”. Previous announcements include:

  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programs for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year program to fund independent training programs in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.


GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

GSK R&D China

Established in 2007, GSK R&D China is dedicated to the discovery and development of medicines for patients worldwide, and to helping address unmet medical needs for patients in China. 


GSK enquiries:




Susan Song            (Shanghai)